Document Library

Click the icons below to search through Pioneer’s reports and documents.

Filename RareDiseasePaper-WP.pdf
Filesize 753 KB
Version 1
Date added June 21, 2019
Downloaded 769 times
Category Health Care, Life Sciences, Price Transparency, White Papers

Date: June 21, 2019

Author: Dr. William Smith

This report examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.